Michael Hayden
Founder chez 89BIO, INC.
Fortune : 11 M $ au 31/03/2024
Profil
Michael R.
Hayden is the founder of Aspreva Pharmaceuticals Corp.
(founded in 2002) and Centre for Molecular Medicine & Therapeutic (founded in 1992).
He is also the founder of NeuroVir Therapeutic, Inc., Prilenia Therapeutics Development Ltd., and 89bio, Inc. (founded in 2018).
Currently, Dr. Hayden holds positions as an Independent Director at Ionis Pharmaceuticals, Inc. (since 2018), a Non-Executive Director at Oxford Biomedica Plc (since 2021), and a Director-Translational Laboratory at the National University of Singapore.
He is also a Scientific Director at the Canadian Genetics Diseases Network (since 1990), a Director at the Royal Society of Canada (since 1995), a Lead Director at AbCellera Biologics, Inc. (since 2019), a Director & Program Director at the Translational Laboratory in Genetic Medicine, a Venture Advisor at Andera Partners SCA (since 2018), a Professor at the University of British Columbia (since 1983), a Venture Partner at Forbion Capital Partners Management Holding BV (since 2022), and a Member of the American Society of Clinical Investigation (since 1992).
In his former positions, Dr. Hayden served as a Director at Lycera Corp., Many Bright Ideas Technologies, Inc., and the Agency for Science, Technology & Research.
He was also a Director at the Michael Smith Foundation for Health Research (2011-2012), an Independent Director at Aurinia Pharmaceuticals, Inc. (2018-2021), the Chief Scientific Officer at Teva Pharmaceutical Industries Ltd.
(2013-2017), and the President & Chief Scientific Officer at GlobaR&D Co., Ltd.
Dr. Hayden obtained his undergraduate and doctorate degrees from the University of Cape Town in 1975 and 1979, respectively.
Dr. Hayden is also the founder of NeuroVir Therapeutic, Inc., Prilenia Therapeutics Development Ltd...
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 22/09/2023 | 1 441 642 ( 0,49% ) | 7 M $ | 31/03/2024 | |
89BIO INC
0,26% | 01/02/2024 | 246 430 ( 0,26% ) | 3 M $ | 31/03/2024 |
| 17/07/2023 | 32 219 ( 0,02% ) | 1 M $ | 31/03/2024 | |
OXFORD BIOMEDICA PLC
0,04% | 13/11/2023 | 39 973 ( 0,04% ) | 101 497 $ | 31/03/2024 |
Postes actifs de Michael Hayden
| Sociétés | Poste | Début |
|---|---|---|
| IONIS PHARMACEUTICALS, INC. | Director/Board Member | 24/09/2018 |
| 89BIO, INC. | Founder | 01/04/2018 |
| ABCELLERA BIOLOGICS INC. | Director/Board Member | 01/10/2019 |
| OXFORD BIOMEDICA PLC | Director/Board Member | 15/07/2021 |
Andera Partners SCA
 Andera Partners SCA Investment ManagersFinance Andera Partners SCA (Andera Partners) is a private equity firm founded in 2001 by Pierre-Michel Passy. The firm is headquartered in Paris, France. | Consultant / Advisor | 01/01/2018 |
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Private Equity Investor | 31/03/2022 |
Prilenia Therapeutics BV
 Prilenia Therapeutics BV BiotechnologyHealth Technology Prilenia Therapeutics BV develops and manufactures pharmaceuticals. The company was founded in 2018 and is headquartered in Naarden, the Netherlands. | Founder | 01/10/2018 |
| National University of Singapore | Corporate Officer/Principal | - |
| American Society of Clinical Investigation | Corporate Officer/Principal | 01/01/1992 |
| ░░░░░░░░░░░░░ ░░░░░░░░░░ ░░ ░░░░░░░ ░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Anciens postes connus de Michael Hayden
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░ ░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░░░░░░░░░ ░░░░░░░░░░ ░░░░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░ ░░░░░░░░░░ ░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░ ░░░░░░░░░ ░░░░░░░░ ░░░░░ ░░░░░░░░░░░ | ░░░░░░░ | ░░░░░░░░░░ |
Formation de Michael Hayden
| University of Cape Town | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 7 |
|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Health Technology |
| IONIS PHARMACEUTICALS, INC. | Health Technology |
| OXFORD BIOMEDICA PLC | Health Technology |
| XENON PHARMACEUTICALS INC. | Health Technology |
| MANY BRIGHT IDEAS TECHNOLOGIES INC. | Health Services |
| AURINIA PHARMACEUTICALS INC. | Health Technology |
| 89BIO, INC. | Health Technology |
| Entreprise privées | 17 |
|---|---|
Aspreva Pharmaceuticals Corp.
 Aspreva Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Aspreva Pharmaceuticals Corp. manufactured pharmaceutical products. It offered therapeutic products, research equipment, and related services. The firm developed drugs for the treatment of cancer, infectious diseases, and immune disorders. The company was founded in 2001 and is headquartered in Victoria, Canada. | Health Technology |
Lycera Corp.
 Lycera Corp. Pharmaceuticals: MajorHealth Technology Lycera Corp. develops novel oral medicines for treating autoimmune diseases and cancer. It specializes in immune metabolism, cell signaling and immune cell differentiation. The firm designed gut-directed ATPase modulator, designated LYC-30937, for the treatment of inflammatory bowel disease, and oral RORgamma agonists for diverse applications in immune-oncology. The company was founded in 2006 by Anthony William Opipari, Jr., and Gary D. Glick and is headquartered in Ann Arbor, MI. | Health Technology |
Andera Partners SCA
Andera Partners SCA Investment ManagersFinance Andera Partners SCA (Andera Partners) is a private equity firm founded in 2001 by Pierre-Michel Passy. The firm is headquartered in Paris, France. | Finance |
Agency for Science, Technology & Research
 Agency for Science, Technology & Research Miscellaneous Commercial ServicesCommercial Services Agency for Science, Technology & Research engages in fostering scientific research and development. It is the agency for fostering world-class scientific research and talent for a vibrant knowledge-based and innovation-driven Singapore. The company was founded in 1991 and is headquartered in Singapore. | Commercial Services |
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Finance |
Michael Smith Foundation for Health Research
 Michael Smith Foundation for Health Research Investment Trusts/Mutual FundsMiscellaneous The Michael Smith Foundation for Health Research operates as a health research funding agency. The non-profit company is based in Vancouver, Canada. Diane Finegood has been the CEO of the Canadian company since 2012. | Miscellaneous |
American Society of Human Genetics
 American Society of Human Genetics Miscellaneous Commercial ServicesCommercial Services The American Society of Human Genetics operates as a membership organization for human geneticists. The non-profit company is based in Bethesda, MD. | Commercial Services |
| American Society of Clinical Investigation | |
Canadian Genetics Diseases Network
 Canadian Genetics Diseases Network Miscellaneous Commercial ServicesCommercial Services Canadian Genetics Diseases Network provides research and development services to the healthcare industry. The company is headquartered in Vancouver, Canada. | Commercial Services |
Royal Society of Canada
 Royal Society of Canada Miscellaneous Commercial ServicesCommercial Services The Royal Society of Canada offers educational courses. The non-profit company is based in Ottawa, Canada. The CEO of the Canadian company is Iris Almeida-Cote. | Commercial Services |
| Centre for Molecular Medicine & Therapeutic | |
NeuroVir Therapeutic, Inc.
 NeuroVir Therapeutic, Inc. Pharmaceuticals: MajorHealth Technology Part of MediGene AG, NeuroVir Therapeutic, Inc. develops herpes simplex virus technologies for the treatment of tumors and for gene delivery. The private company is based in San Diego, CA. The company was founded by Michael R. Hayden, Frank Tufaro. NeuroVir Therapeutic was acquired by MediGene AG on January 12, 2001 for $53 million. | Health Technology |
| AbCellera Biologics, Inc. | |
| Translational Laboratory in Genetic Medicine | |
Prilenia Therapeutics Development Ltd.
 Prilenia Therapeutics Development Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Prilenia Therapeutics BV, Prilenia Therapeutics Development Ltd. is a clinical stage biotech company based in Herzliya, Israel. Prilenia Therapeutics is developing its lead drug candidate, pridopidine, which is a sigma-1 receptor agonist and is in clinical development for the treatment of ALS and Huntington's disease. Pridopidine is currently part of the Healey ALS platform phase 2/3 clinical study and is in a phase 3 trial (PROOF-HD) with the Huntington Study Group, addressing functional capacity in early-stage HD patients. The pridopidine pipeline includes further indications in the pre-clinical phase. The Israeli company was founded by Michael R. Hayden in 2018 with the purpose of developing treatments for neurodegenerative and neurodevelopmental disorders. | Commercial Services |
Prilenia Therapeutics BV
Prilenia Therapeutics BV BiotechnologyHealth Technology Prilenia Therapeutics BV develops and manufactures pharmaceuticals. The company was founded in 2018 and is headquartered in Naarden, the Netherlands. | Health Technology |
| GlobaR&D Co. ,Ltd |
